251 286 - Biotech Bayern

Recommendations

Info

18 More about the Finance Climate VC investments in biotechnology companies In 2007, around $ 5.4 billion in venture capital was invested in young biotech companies in the USA, but only around $ 1.5 billion in Europe. Of this sum, around � 440 million was invested in the German Life Science sector (i.e. around $ 660 million, just about half of the VC finance volume invested in Europe as a whole). [Source: VC-facts; transkript] If one subjects these German finance volumes to closer scrutiny, it becomes apparent that only a fifth of them were first financing rounds, and that most of them, however, were third or even later rounds – proof of the difficulties that particularly young companies are still experiencing. Investments in Bavaria Following the ongoing trend over the last few years, the volume of external funding continues to decrease. In 2007, there were no IPOs of Bavarian biotech firms and the VCrounds and follow-on financing of listed companies merely added up to 209 Mio. � (2006: 240 Mio. � plus an IPO- Volume of about 150 Mio. �). There is a fundamental change taking place with Bavarian biotech SMEs gaining massive financing values by “Big Deals” (a more then tenfold increase since 2006!). Company Date Raised Funds Type [Mio. �] GPC Biotech AG Jan 07 33,6 Follow-on MediGene AG Feb 07 12,6 Follow-on Schmack Biogas AG Feb 07 27,20 Follow-on 4SC AG Mai 07 3,40 Follow-on MorphoSys AG Mai 07 32,60 Follow-on Kinaxo Biotechnologies GmbH Mai 07 k.A. VC SpheroTec GmbH Mai 07 0,68 VC (HTGF)* Micromet Inc. Jun 07 25,00 Follow-on Biocam GmbH Jul 07 2,00 VC + Silent Partnership Diaferon GmbH Jul 07 0,68 VC (HTGF) Proteros biostructures GmbH Aug 07 1,0 VC 4SC AG Sep 07 16,78 Follow-on MediGene AG Sep 07 15,60 Follow-on Sirion GmbH Sep 07 k.A. VC (HTGF)* Antisense Pharma GmbH Nov 07 27,00 VC Sloning BioTechnology Nov 07 4,70 VC * HTGF = HighTech Gründer Fond EXTERNAL FINANCING Mio. � 800 700 600 500 400 300 200 100 0 Cooperations (public.) Follow-On IPO VC + Silent Partnerships 151,4 149,5 76,7 64 166,8 38,2 683 2006 2007
Revenues To improve comparability, the following details focus on the published business data of listed Bavarian biotechnology companies. Their stated revenues for 2007 add up to 286 Mio. �. In relation to the number of employees in those listed companies, the per-capita sales volume is 238.000 �. Considering that in 2006, the revenues of the listed biotech SMEs in Munich alone comprised of about 150 Mio. �, which represents approx. 60% of the revenues achieved by all biotech companies in the area, one can assume that the revenues of all the Bavarian biotech SMEs in 2007 will have reached about 400 Mio. �. Summary This shows that, all in all, Bavarian biotech companies are increasingly successful, thanks to their product developments, in securing partnerships or finance involving huge sums, thus making themselves more and more independent of volatile financial markets and capital-market instruments. The Bavarian biotech industry can look back on a history that has developed over some decades, a history with more ups than downs. REVENUES TOTAL IN MIO. �, LISTED COMPANIES 2006 2007 251 286 Within a period of about 15 years, an industry employing around 25,000 people established itself, creating newly around 20,000 jobs. By gaining federal fundings of about 150 Mio. � the further privatly investments of about 2.5 Billion � could be attracted. The companies have reached a level of maturity that allows them increasingly to enter into cooperations involving huge sums: after a build-up phase that lasted many years, for many companies the harvest has now begun. This holds out hope for the future! 19
Page 3 and 4: Biotechnology in Bavaria 2007 3
Page 5 and 6: Content Welcome notes 06-07 Emilia
Page 7: Especially biotechnology has to rel
Page 11 and 12: The Companies in the Bavarian Biote
Page 13 and 14: SIZE OF BIOTECH SME BY NUMBER OF EM
Page 16 and 17: 16 M&A Activities, Cooperations and
Page 20 and 21: 20 Endurance and stamina: Biotech e
Page 22 and 23: 22 The BioTech Region Munich-Martin
Page 24: 24 Helmholtz Zentrum München More
Page 27 and 28: GmbH was awarded the Bavarian Innov
Page 29 and 30: CO2 output. This is where white bio
Page 31 and 32: Directly opposite, one year later,
Page 33 and 34: With new laboratory tests (in vitro
Page 35: Central tasks are: general coaching
Page 38 and 39: Contact: Bettina von Klitzing Am Kl
Page 40 and 41: Contact: Silvia Schmidt Hanauerstr.
Page 42 and 43: Contact: Prof. Dr. Gottfried Brem T
Page 44 and 45: Contact: Derek Beggs Fraunhoferstr.
Page 46 and 47: Contact: Lydia Krybus Carl-Zeiss-Ri
Page 48 and 49: Contact: Dr. Alexander von Niecieck
Page 50 and 51: Contact: Dr. T. Polifke Eggenwatt 1
Page 52 and 53: Contact: Dr. Andrea Kofler Mühlens
Page 54 and 55: Contact: Dr. Günter Wich Zielstatt
Page 56 and 57: Contact: Dr. Bettina Kipp Grillparz
Page 58 and 59: Contact: Dr. Franz Kerek Am Klopfer
Page 60 and 61: Contact: Christiane Proll St.-Veit-
Page 62 and 63: Contact: Felix Raslag Am Klopferspi
Page 64 and 65: Contact: Thomas Kratzmüller Floria
Page 66 and 67: Contact: Dr. Albert Röder Am Neula
Page 68 and 69:
Contact: Jasmin Amstadt Lessingstr.
Page 70 and 71:
Contact: Kurt Martin Postfach 1351
Page 72 and 73:
Contact: Simon Herzog Am Klopferspi
Page 74 and 75:
Contact: Rudolf-Diesel-Str. 8A D-97
Page 76 and 77:
Contact: Prof. Dr. Toni Lindl Balan
Page 78 and 79:
Contact: Dr. Klaus Hellmann Geyersp
Page 80 and 81:
Contact: Prof. Dr. Peter Schlieper
Page 82 and 83:
Contact: Dieter Meyer Paul-Gerhardt
Page 84 and 85:
Contact: Prof. Dr. Dr. Torsten Hafe
Page 86 and 87:
Contact: Dr. Lukas Pfister Lindenpl
Page 88 and 89:
multi-servicemonitoring Contact: Dr
Page 90 and 91:
Contact: Dr. Klaus-Peter Stengele B
Page 92 and 93:
Contact: Michael Almstetter Am Klop
Page 94 and 95:
Contact: Dr. Frank Hensel Friedrich
Page 96 and 97:
Contact: Rita Fischer Lise-Meitner-
Page 98 and 99:
Contact: Dr. Christian Philipp Erns
Page 100 and 101:
Contact: Stefan Schöffel Mühlweg
Page 102 and 103:
Contact: Dr. Ortwin Faff Carl-von-L
Page 104 and 105:
Contact: Dr. Brigitte Hanke Freisin
Page 106 and 107:
Contact: Prof. Dr. Peter Buckel Am
Page 108 and 109:
Contact: Marcus Irsfeld Fraunhofers
Page 110 and 111:
Contact: Martina Frauscher Emmy-Noe
Page 112 and 113:
Contact: Rachela Mohr Hanns-Seidel-
Page 114 and 115:
114
show all

251 286 - Biotech Bayern

Create successful ePaper yourself

Delete template?

Save as template?